• ImmunityBio recently became the focus of retail speculation that it could shift from the Russell 2000 to the Russell 1000, based on index cutoff levels and potential rebalancing effects.
• This episode highlights how expectations around index inclusion alone can meaningfully influence trading behavior and sentiment among retail and institutional investors.
• We’ll now examine how the possibility of a Russell 1000 move and higher passive ownership could shape ImmunityBio’s investment narrative.

Find 43 companies with promising cash flow potential yet trading below their fair value.

What Is ImmunityBio's Investment Narrative?

To own ImmunityBio, you need to be comfortable backing a high-spend oncology platform where ANKTIVA’s commercial ramp and additional NMIBC and NSCLC indications are central to the story, while losses remain very large and cash runway is tight. The recent Russell 1000 speculation sits mostly around the edges of that thesis: a possible index move could influence near term liquidity, volatility and passive ownership, but it does not change the core clinical, regulatory and funding milestones that matter most. With the FDA reviewing an sBLA for papillary NMIBC, a PDUFA date in early 2027, conditional approval already in Europe and ongoing capital raises that dilute existing holders, the key short term catalysts and risks are still rooted in trial outcomes, label expansions, reimbursement traction and the company’s ability to finance its plans. But there is one funding risk in particular that current and prospective shareholders should not ignore.

ImmunityBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span roughly US$1 to US$36 per share, underscoring how far apart individual views sit. Set against that wide dispersion, ImmunityBio’s heavy losses and limited cash runway keep financing risk front and center for many investors, with clear implications for dilution and execution.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 50 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.